 DUBLIN, Ireland, Oct. 15, 2021 GLOBE NEWSWIRE -- Avadel Pharmaceuticals plc Nasdaq: AVDL, a company focused on transforming medicines to transform lives, announced today that the U.S. Food and Drug Administration FDA notified the company that the review of the New Drug Application NDA for FT218 is still ongoing, and action will likely not be taken in October. The FDA informed the company that there are no information requests at this time and a new target action date will be provided as soon as possible. 